| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6200740 | Ophthalmology | 2015 | 13 Pages |
Abstract
In eyes with neovascular age-related macular degeneration (AMD), SHRM is common and often persists after anti-vascular endothelial growth factor treatment. At 2 years, eyes with scar were more likely to have SHRM than other eyes. Greater SHRM dimensions were associated with worse VA. In eyes with neovascular AMD, SHRM is an important morphologic biomarker.
Keywords
CNVCATTCFPAMDRPESHRMHIPAAPRNChoroidal neovascularizationgeographic atrophyfluorescein angiographyELMretinal pigment epitheliumOctOptical coherence tomographyVisual acuitystandard errorTime domainSpectral domainage-related macular degenerationexternal limiting membraneVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Health Insurance Portability and Accountability ActComparison of Age-Related Macular Degeneration Treatments Trialsellipsoid zonesubretinal hyperreflective material
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Alex S. BS, Gui-shuang PhD, Cynthia A. MD, Maureen G. PhD, Russell E. AAS, Juan E. MD, Ebenezer MBBS, MD, Glenn J. MD,